NEW YORK, NY / ACCESSWIRE / April 21, 2016 / Today, ValuableInvestment.com look at four equities in the Major Drug Manufacturers space: Bristol-Myers Squibb Co. (NYE: BMY), Eli Lilly and Co. (NYSE: LLY), AstraZeneca PLC (NYSE: AZN), and GlaxoSmithKline PLC (NYSE: GSK). Access the trade alerts on these stocks at:
http://valuableinvestment.com/freealerts
Shares in Bristol-Myers Squibb Co. ended Wednesday's session 0.46% higher at $69.23. The stock recorded a trading volume of 6.91 million shares, which was above its three months average volume of 6.63 million shares. The Company’s shares have gained 11.07% in the last one month, 9.59% over the previous three months, and 1.24% on an YTD basis. The stock is trading 8.38% above its 50-day moving average and 8.74% above its 200-day moving average. Moreover, shares of Bristol-Myers Squibb have a Relative Strength Index (RSI) of 74.73. Register now and access free trade alerts on BMY at:
http://valuableinvestment.com/BMY
Eli Lilly and Co.'s stock saw a slight correction of 0.22%, closing the day at $77.08 with a total volume of 4.05 million shares traded. The Company's shares have advanced 9.72% in the last month. The stock is trading 5.30% above its 50-day moving average. Additionally, shares of Eli Lilly have an RSI of 66.56. Visit us today and activate your complimentary trade alerts on LLY at:
http://valuableinvestment.com/LLY
On Wednesday, AstraZeneca PLC's shares recorded a trading volume of 3.51 million shares. The stock ended the day 0.26% lower at $30.17. Shares of the Company have advanced 6.23% in the past month and 1.22% in the previous three months. The stock is trading above their 50-day moving average by 4.24%. Furthermore, AstraZeneca's shares have an RSI of 62.87. Trade alert on AZN is available for free at:
http://valuableinvestment.com/AZN
GlaxoSmithKline PLC's stock saw a slight correction of 0.62%, finishing yesterday's session at $43.02, and with a total volume of 2.85 million shares traded. The Company's shares have advanced 7.63% in the last one month, 13.98% in the previous three months, and 10.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.30% and 8.88%, respectively. Additionally, shares of GlaxoSmithKline have an RSI of 68.84. Complimentary alert on GSK is accessible at:
http://valuableinvestment.com/GSK
--
About ValuableInvestment.com:
Valuable Investment was founded in 2006 and has been successfully alerting investors and shareholders of the most profitable ways to earn a living on Wall Street. A decade is a very long time so we must be doing something right. We encourage everyone to come and try our strategy and see how we have been changing the foundation of research for years.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY
ValuableInvestment.com, the Author, the Reviewer, and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither valuableinvestment.com nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our disclosures, or for more information, visit http://valuableinvestment.com/
RESTRICTIONS
ValuableInvestment.com is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: press@valuableinvestment.com
SOURCE: ValuableInvestment.com
ReleaseID: 439069
